Immunotherapy for pregnant women and newborns

Annals of the New York Academy of Sciences

Volumn 918, Issue , 2000, Pages 313-317

  Borkowsky, W ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ZIDOVUDINE;

CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; PLACENTAL TRANSFER; PREGNANCY; VIRUS TRANSMISSION;

EID: 0033637813     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb05500.x     Document Type: Conference Paper

References (22)

1. Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit Human Immunodeficiency Virus to their infants
2. Immunization during pregnancy
3. Maternal immunization with vaccines for H. influenza type b
4. Maternal immunization against viral disease
5. Maternal immunization for the prevention of bacterial infection in young infants
6. Fetal immunization of baboons induces a fetal-specific antibody response
7. Transplacental immunization of the human fetus to tetanus by immunization of the mother
8. In utero immunization of the fetus to tetanus by maternal vaccination during pregnancy
9. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants
10. Immunization with envelope MN rgp 120 vaccine in human immunodeficiency virus-infected pregnant women
11. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency
12. Induction of specific T-cell responses in HIV infection
13. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators
14. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects
15. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
16. Eficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of Pediatric AIDS Clinical Trials Group Protocol 185
17. Transport of recombinant human CD4-immunoglobulin G across the human placenta: Pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146
18. Cytotoxic T cells and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
19. Immune response to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults
20. A canarypox vaccine expressing multiple HIV type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
21. Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees
22. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV